Table 2.
Diagnostic measures in simulated brain biopsy
| Disease | AD | CBD | FTLD-TDP | LBD | MSA | PSP | PiD | Control | Overall |
|---|---|---|---|---|---|---|---|---|---|
| Number of subjects | 10 | 6 | 9 | 19 | 7 | 9 | 6 | 7 | 73 |
| Correct diagnosis (n) | |||||||||
| Frontal | 8 | 4 | 8 | 15 | 5 | 0 | 4 | 3 | 47 |
| 4 region | 8 | 5 | 9 | 19 | 7 | 8 | 6 | 5 | 67 |
| Sensitivity (%) | |||||||||
| Frontal | 80 | 66 | 88 | 79 | 71 | 0 | 66 | NA | 64 |
| Lower CI | 55 | 29 | 68 | 61 | 38 | 0 | 28 | NA | 40 |
| Upper CI | 100 | 100 | 100 | 97 | 100 | 0 | 100 | NA | 85 |
| 4 region | 80 | 83 | 100 | 100 | 100 | 88 | 100 | NA | 92 |
| Lower CI | 55 | 53 | 100 | 100 | 100 | 68 | 100 | NA | 82 |
| Upper CI | 100 | 100 | 100 | 100 | 100 | 100 | 100 | NA | 100 |
| Specificity (%) | |||||||||
| Frontal | NA | NA | NA | NA | NA | NA | NA | 43 | 43 |
| Lower CI | NA | NA | NA | NA | NA | NA | NA | 6 | 6 |
| Upper CI | NA | NA | NA | NA | NA | NA | NA | 79 | 79 |
| 4 region | NA | NA | NA | NA | NA | NA | NA | 71 | 71 |
| Lower CI | NA | NA | NA | NA | NA | NA | NA | 38 | 38 |
| Upper CI | NA | NA | NA | NA | NA | NA | NA | 100 | 100 |
| PLR | |||||||||
| Frontal | 1.4 | 1.2 | 1.5 | 1.4 | 1.2 | 0 | 1.2 | NA | 1.1 |
| 4 region | 2.8 | 2.9 | 3.5 | 3.5 | 3.5 | 3.1 | 3.5 | NA | 3.2 |
| NLR | |||||||||
| Frontal | 0.5 | 0.7 | 0.2 | 0.5 | 0.6 | 2.3 | 0.7 | NA | 0.8 |
| 4 region | 0.3 | 0.2 | 0 | 0 | 0 | 0.1 | 0 | NA | 0.1 |
CI confidence interval. Lower CI Lower Limit of CI, Upper CI upper Limit of CI, PLR positive diagnostic likelihood ratio, NLR negative diagnostic likelihood ratio, NA not applicable, AD Alzheimer’s disease, LBD Lewy body disease, FTLD-TDP frontotemporal dementia-Tar DNA binding protein 43, MSA multiple system atrophy, PiD Pick’s disease, CBD corticobasal degeneration, PSP progressive supranuclear palsy